KKR-backed Biosynth Carbosynth acquires vivitide
Biosynth Carbosynth, which is backed by KKR, has acquired vivitide, a provider of custom peptides and antibodies for the life sciences and biotech industry.
17 March 2022•3 mins read
Biosynth Carbosynth, which is backed by KKR, has acquired vivitide, a provider of custom peptides and antibodies for the life sciences and biotech industry.
Walter Capital Partners takes significant stake in Quebec educational games maker Passe-Temps
12 hours ago · 1 min read
Truelink Capital’s GES buys CSG Creative from National Trade Productions
12 hours ago · 2 mins read
MPE Partners’ Intermatic adds outdoor lighting-control products maker Sun-Tech
12 hours ago · 2 mins read
Velocity Capital Management backs founder Griffin Haddrill with stake in LV8, Mirage
13 hours ago · 1 min read
Aterian’s Outlook Group completes acquisition of Graham-backed ABX’s Pewaukee packaging facility
13 hours ago · 1 min read
FPE Capital’s NoBlue2 adds PeopleWalking’s Spanish NetSuite business in Europe push
13 hours ago · 1 min read
PE targets identity security as AI transforms threats: 6 deals
15 hours ago · 3 mins read
